SCHEMBL23207670

SCHEMBL23207670

O=C(Nc1ccc(C(F)(F)F)c(F)c1)Nc1c[nH]c2ccc(-c3cccc(CO)c3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 8/20 0.48
▸ TRPV1 Q8NER1 3/20 0.43
▸ KIF11 P52732 1/20 0.41
▸ LYN P07948 2/20 0.41
▸ IGF1R P08069 2/20 0.41
▸ IKBKB O14920 1/20 0.41
▸ CHUK O15111 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ CSF1R P07333 2/20 0.40
▸ FGFR1 P11362 2/20 0.40
▸ FLT1 P17948 2/20 0.40
▸ FLT4 P35916 2/20 0.40
▸ KDR P35968 2/20 0.40
▸ FLT3 P36888 2/20 0.40
▸ AURKB Q96GD4 2/20 0.40
▸ PLK4 O00444 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207913 0.87 STING1 (0.62) STING1TRPV1LYNIGF1RIKBKB
SCHEMBL30195943 0.87 STING1 (0.62) STING1TRPV1LYNIGF1RIKBKB
SCHEMBL23207669 0.84 STING1 (0.48) STING1TRPV1LYNIGF1RIKBKB
SCHEMBL30885396 0.83 STING1 (0.46) STING1TRPV1KIF11LYNCSF1R
SCHEMBL23208029 0.80 STING1 (0.60) STING1TRPV1LYNIGF1RIKBKB
SCHEMBL30195946 0.80 STING1 (0.60) STING1TRPV1LYNIGF1RIKBKB
SCHEMBL23208227 0.78 STING1 (0.62) STING1TRPV1KIF11LYNIGF1R
SCHEMBL23207674 0.77 STING1 (0.44) STING1LYNCSF1RFGFR1FLT1
SCHEMBL23207648 0.77 STING1 (0.42) STING1LYNCSF1RFGFR1FLT1
SCHEMBL30196123 0.76 STING1 (0.58) STING1TRPV1LYNIGF1RIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885TRPV1 671/4885KIF11 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback